Tivantinib

Generic Name: Tivantinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₉N_₃O_₂

CAS Number: 905854-02-6

Unique Ingredient Identifier: PJ4H73IL17

Background: Tivantinib has been investigated in Solid Tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2

Terminated

Conditions: Epithelioid Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatoid Mesothelioma
Stage II Pleural Mesothelioma
Stage III Pleural Mesothelioma
Stage IV Pleural Mesothelioma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tivantinib

First Posted Date: 2013-05-23

Last Posted Date: 2016-10-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01861301

Locations: 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States

and more 15 locations

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Solid Neoplasm

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tivantinib

First Posted Date: 2012-12-13

Last Posted Date: 2017-10-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT01749384

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Childhood Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tivantinib

First Posted Date: 2012-11-12

Last Posted Date: 2015-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT01725191

Locations: 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 17 locations

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Carcinoma

Interventions: Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Drug: Tivantinib

First Posted Date: 2012-10-02

Last Posted Date: 2018-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT01696955

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States

and more 21 locations

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Type 1 Papillary Renal Cell Carcinoma
Type 2 Papillary Renal Cell Carcinoma
Stage III Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Tivantinib

First Posted Date: 2012-09-20

Last Posted Date: 2019-01-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT01688973

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States

and more 211 locations

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pegfilgrastim
Other: Pharmacological Study
Drug: Tivantinib
Drug: Topotecan Hydrochloride

First Posted Date: 2012-08-01

Last Posted Date: 2018-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT01654965

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 4 locations

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus
Drug: Tivantinib

First Posted Date: 2012-06-21

Last Posted Date: 2015-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT01625156

Locations: 🇺🇸
Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Negative
Recurrent Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Negative
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tivantinib

First Posted Date: 2012-04-11

Last Posted Date: 2016-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01575522

Locations: 🇺🇸
Dana-Farber Cancer Institute Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tivantinib
Other: Placebo

First Posted Date: 2012-01-27

Last Posted Date: 2018-09-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT01519414

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸
University of Maryland Saint Joseph Medical Center, Towson, Maryland, United States

and more 17 locations

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: Tivantinib
Other: Diagnostic laboratory biomarker analysis
Other: Questionnaire administration
Procedure: Quality-of-life assessment

First Posted Date: 2011-10-06

Last Posted Date: 2019-08-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01447914

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy